In this issue:
CYKLONE for newly diagnosed myeloma
New prognostic staging for MM in the novel therapeutic agent era
30-min carfilzomib infusions ±low-dose dexamethasone in relapsed/refractory MM
Novel prognostic biomarkers and insights into signalling pathways in MM
VTD consolidation in MM: impact of MRD on survival
MDX-1097 in κ-MM cells, and the effect of lenalidomide
Bendamustine/thalidomide/ dexamethasone in bortezomib- and lenalidomiderefractory MM
Treating MM patients aged >65 years
Pomalidomide + low-dose dexamethasone in MM with del(17p)) and t(4;14)
Survival predictors in phase 1 relapsed /refractory MM
Please login below to download this issue (PDF)